September 1, 2023
Reston, VA—The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy. The statement, published in The Journal of Nuclear Medicine, also reviews current clinical struggles physicians face during treatment with 177Lu-PSMA-617 radionuclide therapy.
Recently, the U.S. Food and Drug Administration approved 177Lu-PSMA-617 for the treatment of men with mCRPC after progressing on taxane-based chemotherapy and at least one line of androgen receptor pathway inhibitors (ARPI). To develop the patient selection criteria and determine appropriate use scenarios, SNMMI assembled an autonomous workgroup to represent a multidisciplinary panel of health care providers with substantive knowledge in the use of nuclear medicine in 177Lu-PSMA-617 radionuclide therapy. The workgroup conducted a review of the four prospective phase 2 and phase 3 trials that used 177Lu-PSMA-617 registered on clinicaltrials.gov to develop consensus recommendations.
In terms of patient selection, workgroup members agreed that PSMA PET should be performed within three months of treatment or since progression on the last therapy to ensure that the current disease state is represented. If disease progression or intervening therapy is evident, PSMA PET should be repeated. Either 18F-DCFPyL or 68Ga-PSMA-11 can be used for PSMA PET imaging, and 18F-FDG PET is not required as a standard patient selection tool. In addition, patients should be imaged with either contrast-enhanced CT or MRI to identify potential PSMA-negative disease. Baseline requirements for renal and bone marrow functions were also noted.
Treatment of mCRPC after chemotherapy and ARPI was considered appropriate, while treatment of mCRPC after ARPI and before chemotherapy was considered rarely appropriate. The working group also agreed that treatment of patients with metastatic castration-sensitive prostate cancer was rarely appropriate.
Furthermore, the consensus statement addressed current clinical struggles that physicians face when administering 177Lu-PSMA-617 radionuclide therapy. These include the role of androgen receptor-targeted therapies, the role of 223Ra, treatment-related toxicities, when to consider cessation of treatment, exceptional responders and restarting treatment, and imaging during treatment.
“With the approval of 177Lu-PSMA-617, a new class of therapeutics is available to patients with prostate cancer. We look forward to the potential use of PSMA radionuclide therapy in pre-chemotherapy mCRPC or other settings pending the full results of ongoing trials,” noted the authors.
The full consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radionuclide therapy can be viewed on SNMMI’s website.
The authors of “SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy” include Thomas A. Hope, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; Emmanuel S. Antonarakis, 2 University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota; Lisa Bodei, Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; Jeremie Calais, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; Amir Iravani, Department of Radiology, University of Washington, Seattle, Washington; Heather Jacene, Department of Radiology, Brigham and Women’s Hospital, and Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts; Phillip J. Koo, Banner M.D. Anderson Cancer Center, Phoenix, Arizona; Alicia K. Morgans and Mary-Ellen Taplin, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Joseph R. Osborne, Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, New York; Scott T. Tagawa, Department of Medicine, Weill Cornell Medical College, New York, New York; Oliver Sartor, Mayo Clinic, Rochester, Minnesota; and Michael J. Morris, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or email@example.com.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.